Sepsis criteria, pneumonia severity (CURB-65), antimicrobial stewardship, and mortality scores.
Predicts in-hospital mortality in patients admitted with COVID-19
Predicts response to therapy in C. diff patients
IDSA/SHEA severity classification for C. difficile infection.
Predicts probability of undiagnosed HIV infection in patients aged 13 and older using demographic and behavioral risk factors.
Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.
Provides standardized diagnostic criteria for infective endocarditis based on clinical, microbiological, and echocardiographic findings. Classifies patients as having definite, possible, or rejected endocarditis.
Diagnostic criteria for infective endocarditis, updated from the original Duke criteria with improved sensitivity and specificity.
Predicts likelihood of streptococcal pharyngitis and guides antibiotic prescribing decisions.
Interprets HBsAg, anti-HBs and anti-HBc serology into clinical patterns.
Identifies men who have sex with men (MSM) at high risk for HIV infection to prioritize for intensive prevention interventions including pre-exposure prophylaxis (PrEP).
Quantifies HIV exposure risk by source and exposure type to guide post-exposure prophylaxis (PEP) decisions following needle stick injuries or other potential HIV exposures.
Aids in determining if Paxlovid (nirmatrelvir boosted with ritonavir) is appropriate therapy in an adult COVID-19 positive patient. Paxlovid is an oral antiviral treatment authorized for mild-to-moderate COVID-19 in patients at high risk for progression to severe COVID-19, including hospitalization or death. The tool evaluates eligibility based on FDA guidelines including age, weight, symptom duration, disease severity, kidney function, high-risk conditions, and potential contraindications. Proper patient selection is crucial as the medication must be started within 5 days of symptom onset and has significant drug interactions requiring careful evaluation. The assessment helps clinicians systematically determine appropriate candidates for this time-sensitive antiviral therapy.
Predicts 4-year HIV risk for men who have sex with men (MSM) based on sexual behavior and substance use factors. Developed to help identify high-risk individuals for targeted HIV prevention interventions.
Modified Duke criteria for infective endocarditis (Li 2000): count major (0-2) and minor (0-5) criteria. Definite: 2 major, or 1 major + 3 minor, or 5 minor. Possible: 1 major + 1 minor, or 3 minor.
Risk-stratifies reported penicillin allergy: very low risk patients may proceed to direct oral challenge.
PEN-FAST penicillin allergy risk score (Trubiano 2020) for de-labeling: allergy in last 5 years (2), anaphylaxis/angioedema (2), severe cutaneous adverse reaction (2), treatment required (1); total 0-5. 0 very low, 1-2 low, 3 moderate, 4-5 high risk.
Predict mortality in bloodstream infections.
WHO severe malaria criteria checklist (any one = severe).
Interprets the tuberculin skin test (Mantoux) by induration size using CDC risk-stratified cutoffs: ≥5 mm positive in highest-risk groups (HIV, contacts, immunosuppressed, fibrotic CXR, transplant); ≥10 mm in moderate-risk groups; ≥15 mm in persons with no risk factors.
Estimates 30-day mortality risk after COVID-19 infection using pre-existing health conditions and demographics. Developed by researchers from Yale University and VA Connecticut Healthcare System in collaboration with the US Department of Health and Human Services.
Estimates 5-year all-cause mortality risk in patients with HIV and/or HCV by integrating HIV-specific biomarkers (CD4 count, HIV-1 RNA) with general health indicators (hemoglobin, liver function, kidney function, and hepatitis C co-infection).
Estimates 5-year all-cause mortality risk in patients with HIV using age, HIV-specific biomarkers, and general health indicators. An improved version of the original VACS Index with enhanced discrimination.
Combines the Veterans Aging Cohort Study (VACS) Index with the Charlson Comorbidity Index to provide enhanced mortality risk prediction for patients with HIV. This integrated score incorporates HIV-specific biomarkers, general health indicators, and comprehensive comorbidity assessment to estimate 5-year all-cause mortality risk.
WHO dengue warning signs checklist (2009 guidelines): abdominal pain/tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver enlargement >2 cm, and rising hematocrit with falling platelets. Any warning sign warrants strict observation and medical intervention; absence supports outpatient management with follow-up.
WHO rabies exposure categories: Category I (touching/feeding animals, licks on intact skin) — no PEP; Category II (nibbling of uncovered skin, minor scratches/abrasions without bleeding) — vaccine; Category III (transdermal bites/scratches, licks on broken skin, mucous-membrane contamination, bat exposures) — vaccine plus rabies immunoglobulin.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.